According to the results of a complete clinical trial, its COVID-19 vaccine was “highly effective” in the U.S. in adolescents 12 to 17 years of age. Biotech company Moderna announced on Tuesday.
Also read: Adolescents refrain from vaccinating
Modrana said it plans to file an application for the authority to use their vaccine at this age “with regulators around the world” “in early June”.
Another vaccine, Pfizer / Bioentech, is already licensed for adolescence in many countries, including the United States.
“We are promoting the most effective (vaccine) in preventing COVID-19 in adolescence,” modern boss Stefan Bonsel said in a statement. “We are going to submit these results to the FDA (United States Medicines Agency) and regulators worldwide in early June and seek authorization.”
The Moderna study involved more than 3,700 people aged 12 to 17 in the United States, two-thirds of whom were vaccinated, and one-third had placebo.
“After two doses, no Kovid-19 case was found in the group (…) vaccinated against 4 cases in the placebo group, resulting in 100% effectiveness of the vaccine 100 days after the second dose,” Moderna said in a statement.
After dosing, 93% efficacy was observed, directing the firm.
The vaccine is “generally well tolerated” and “no concerns about its safety have been identified so far,” she said. The observed side effects are similar to those in adults (pain at the injection site, fatigue, chills, etc.).